Autors:

CiteWeb id: 20090000069

CiteWeb score: 5617

DOI: 10.1056/NEJMoa061884

bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P = 0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. Conclusions The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non–small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

The publication "Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer" is placed in the Top 10000 of the best publications in CiteWeb. Also in the category Medicine it is included to the Top 1000. Additionally, the publicaiton "Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer" is placed in the Top 100 among other scientific works published in 2009.
Links to full text of the publication: